Loading...
High Throughput Genomics (HTG) Announces Genomic Screening Technology Agreement with Celgene Corporation
21.08.2002
Tucson, AZ August 19, 2002- High Throughput genomics, Inc. ("HTG") announced today that it has entered into
an agreement with Celgene Corporation to supply Celgene's target and Drug Discovery platform with HTG's Omix
Imager™ and ArrayPlate™ Kits.
Under the terms of the agreement, HTG will install at Celgene an Omix Imager system for high throughput genomic
screening and will develop and supply ArrayPlate Kits containing sets of genes associated with disease pathways
targeted by Celgene's drug discovery programs. HTG also will develop and supply to Celgene genomic profiling kits
for use in chemicogenomics and pharmacogenomics studies. The ArrayPlate Kits and the Omix Imager will be
incorporated into Celgene's target and drug discovery process and used to detect changes in disease- and drug-associated
gene Expression profiles.
HTG's ArrayPlate consists of a standard 96-well microplate where each individual well can be programmed for the
multiplexed measurement of any set of up to approximately 100 different DNA, RNA or protein target molecules using
custom reagent sets (in the case of RNA and DNA, GeneSets™). The RNA expression and DNA Assays rely on an
optimized and simplified, automation-friendly multiplexed nuclease protection assay (m-NPA™) that requires only the
lysis of samples, with no extraction, purification or amplification needed.
Dr. Alan Lewis, President of the Signal Research Division of Celgene Corporation, commented:
"The technology we are using from HTG will further enhance our proven, state-of-the-art drug discovery capabilities
and allow us to implement pharmacogenomics studies to better understand pathogenesis and management of disease
and ultimately to develop personalized medicine strategies."
Dr. Bruce Seligmann, Chief Executive Officer of High Throughput Genomics said:
"Celgene is a leading drug discovery and development company, and we are excited that they have chosen the
ArrayPlate to screen their compounds. They had a choice of partners and we are delighted that they have elected to
work with HTG."
HTG markets ArrayPlate assays to pharmaceutical researchers who use the product for target validation, compound
screening, safety, and metabolism optimization in drug discovery or diagnostics. Clients can use the ArrayPlate
technology on a service basis or through purchase of custom kits, Software, and imagers, to establish and validate
custom assays, test samples, or perform high throughput screening. and optimization using HTG's proprietary
combinatorial chemistry and libraries.
Weitere News aus dem Ressort Forschung & Entwicklung
Holen Sie sich die Life-Science-Branche in Ihren Posteingang
Ab sofort nichts mehr verpassen: Unser Newsletter für Biotechnologie, Pharma und Life Sciences bringt Sie jeden Dienstag und Donnerstag auf den neuesten Stand. Aktuelle Branchen-News, Produkt-Highlights und Innovationen - kompakt und verständlich in Ihrem Posteingang. Von uns recherchiert, damit Sie es nicht tun müssen.
